

Long-term Obesity Medications Indications Overview

Drug	Brand name(s)	Indication(s)			
		Patient age:	Patient characteristics:	To/For:	In conjunction with:
Orlistat	Xenical		with an initial BMI of ≥ 30 kg/m ² , or ≥ 27 kg/m ² with other risk factors	Obesity management, including weight reduction and weight maintenance	
	Alli		with overweight	Weight reduction	
Phentermine-topiramate	Qsymia		with obesity	Reduce excess body weight and maintain weight reduction long term	 
			with overweight in the presence of at least one weight-related comorbid condition		
Naltrexone-bupropion	Contrave		with an initial BMI of ≥ 30 kg/m ² , or ≥ 27 kg/m ² with other risk factors	Chronic weight management	 

 = age 12+  = age 18+  = reduced-calorie diet  = increased physical activity

XENICAL Prescribing Information. <https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=6240792b-9224-2d10-e053-2a91aa0a2c3e&type=display>. ALLI Approval Letter.

https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021887s000_APPROV.pdf. QSYMIA (PI). <https://qsymia.com/patient/include/media/pdf/prescribing-information.pdf>.

CONTRAVE (PI). <https://www.curraxpharma.com/PI/Contrave-label-current.pdf/>

Long-term Obesity Medications Indications Overview (cont)

Drug	Brand name(s)	Indication(s)			
		Patient age:	Patient characteristics:	To/For:	In conjunction with:
Liraglutide	Saxenda	 	with an initial BMI of ≥ 30 kg/m ² , or ≥ 27 kg/m ² with comorbid condition with body weight above 60 kg and an initial BMI corresponding to ≥ 30 kg/m ² for adults	Chronic weight management	 
	Victoza		with type 2 diabetes	Improve glycemic control	 
			with type 2 diabetes and established CVD	Reduce the risk of MACE	
	Zepbound		with obesity or with overweight and at least one comorbid condition with obesity	Reduce excess body weight and maintain weight reduction long term Moderate to severe obstructive sleep apnea	 
Tirzepatide	Mounjaro		with type 2 diabetes	Improve glycemic control	 

SAXENDA Prescribing Information. <https://www.novo-pi.com/saxenda.pdf>. Victoza Prescribing Information. <https://www.novo-pi.com/victoza.pdf>. Zepbound Prescribing Information. <https://pi.lilly.com/us/zepbound-uspi.pdf>. Mounjaro Prescribing Information. <https://pi.lilly.com/us/mounjaro-uspi.pdf>.

Long-term Obesity Medications Indications Overview (cont)

Drug	Brand name(s)	Indication(s)			
		Patient age:	Patient characteristics:	To/For:	In conjunction with:
Semaglutide	Wegovy (injection)		with obesity		
			with overweight and at least one comorbid condition	Reduce excess body weight and maintain weight reduction long term	
			with CV disease and obesity or overweight	Reduce the risk of MACE	 
			with MASH with moderate to advanced liver fibrosis	Treat MASH	
	Wegovy (oral)		with obesity or overweight and at least one comorbid condition	Reduce excess body weight and maintain weight reduction long term	 
			with established CV disease and either obesity or overweight	Reduce the risk of MACE	 
	Ozempic		with type 2 diabetes	Glycemic control	
			with type 2 diabetes and established CV disease	Reduce the risk of MACE	 
			With type 2 diabetes and chronic kidney disease	Reduce the risk of sustained eGFR decline	 

Wegovy Prescribing Information. <https://www.novo-pi.com/wegovy.pdf>. Ozempic Prescribing Information. <https://www.novo-pi.com/ozempic.pdf>.